About this Research Topic
Urothelial carcinoma (UC) is a worldwide common genitourinary malignancy with approximately 95% of cases found in the bladder (urothelial bladder carcinoma). There are over 500,000 new cases of the disease annually. Although there has been development towards treatment and therapeutic approaches for patients, there continues to be a poor survival rate and prognosis with a high rate of disease recurrence. Therefore, further research is required to investigate molecular therapeutic approaches.
While the approval of Bacillus Calmette-Guérin (BCG) in the 1990s may be considered a targeted therapy of sorts, it is only recently that direct, selective, targeted therapy has been incorporated into standard therapy for UC. In 2019 erdafitinib was approved for UC harbouring fibroblast growth factor receptor (FGFR) mutations. In 2021 enfortumab vedotin-EJFV, an antibody-drug conjugate that targets nectin-4, was also approved. Approval of both of these agents bolsters a renewed interest in selective, direct, targeted therapies for UC.
The goal of this Research Topic is to highlight the need for novel molecular targets and clinically relevant targeted therapies in urothelial carcinoma. We encourage authors to submit Original Research Articles, Case Reports and Review Articles. For the purpose of this Research Topic, targeted therapy is defined as therapy that directly targets dysregulated oncogenic pathways, neoantigens, or otherwise directly selectively targets malignant cells. Example topics would include small molecule inhibitors of oncogenic proteins, antibody-drug conjugates, and identification of cancer neoantigens,
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
While the approval of Bacillus Calmette-Guérin (BCG) in the 1990s may be considered a targeted therapy of sorts, it is only recently that direct, selective, targeted therapy has been incorporated into standard therapy for UC. In 2019 erdafitinib was approved for UC harbouring fibroblast growth factor receptor (FGFR) mutations. In 2021 enfortumab vedotin-EJFV, an antibody-drug conjugate that targets nectin-4, was also approved. Approval of both of these agents bolsters a renewed interest in selective, direct, targeted therapies for UC.
The goal of this Research Topic is to highlight the need for novel molecular targets and clinically relevant targeted therapies in urothelial carcinoma. We encourage authors to submit Original Research Articles, Case Reports and Review Articles. For the purpose of this Research Topic, targeted therapy is defined as therapy that directly targets dysregulated oncogenic pathways, neoantigens, or otherwise directly selectively targets malignant cells. Example topics would include small molecule inhibitors of oncogenic proteins, antibody-drug conjugates, and identification of cancer neoantigens,
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: urothelial carcinoma, bladder cancer, targeted therapy, oncology, cancer, molecular approach, therapeutics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
